Lifileucel
Advanced Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Iovance Biotherapeutics
Iovance Biotherapeutics' mission is to be the global leader in developing and delivering TIL therapy for cancer. Its landmark achievement is the FDA accelerated approval of Amtagvi™ (lifileucel) in February 2024, the first-ever approved TIL therapy, validating its core platform. The company's strategy is to commercialize Amtagvi in melanoma, expand its label into earlier lines of therapy and new tumor types, and advance next-generation genetically modified TIL therapies through its integrated manufacturing facility, the Iovance Cell Therapy Center (iCTC).
View full company profileAbout Iovance Biotherapeutics
Iovance Biotherapeutics' mission is to be the global leader in developing and delivering TIL therapy for cancer. Its landmark achievement is the FDA accelerated approval of Amtagvi™ (lifileucel) in February 2024, the first-ever approved TIL therapy, validating its core platform. The company's strategy is to commercialize Amtagvi in melanoma, expand its label into earlier lines of therapy and new tumor types, and advance next-generation genetically modified TIL therapies through its integrated manufacturing facility, the Iovance Cell Therapy Center (iCTC).
View full company profileAbout Iovance Biotherapeutics
Iovance Biotherapeutics' mission is to be the global leader in developing and delivering TIL therapy for cancer. Its landmark achievement is the FDA accelerated approval of Amtagvi™ (lifileucel) in February 2024, the first-ever approved TIL therapy, validating its core platform. The company's strategy is to commercialize Amtagvi in melanoma, expand its label into earlier lines of therapy and new tumor types, and advance next-generation genetically modified TIL therapies through its integrated manufacturing facility, the Iovance Cell Therapy Center (iCTC).
View full company profileAbout Iovance Biotherapeutics
Iovance Biotherapeutics' mission is to be the global leader in developing and delivering TIL therapy for cancer. Its landmark achievement is the FDA accelerated approval of Amtagvi™ (lifileucel) in February 2024, the first-ever approved TIL therapy, validating its core platform. The company's strategy is to commercialize Amtagvi in melanoma, expand its label into earlier lines of therapy and new tumor types, and advance next-generation genetically modified TIL therapies through its integrated manufacturing facility, the Iovance Cell Therapy Center (iCTC).
View full company profileTherapeutic Areas
Other Advanced Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| BCA101 | Bicara Therapeutics | Phase 1b/2 |